Co-Authors
This is a "connection" page, showing publications co-authored by JORGE E CORTES and CHENG CAMERON YIN.
Connection Strength
0.607
-
Double-hit of FLT3 gene in a fatal case of acute myemonocytic leukaemia. J Clin Pathol. 2013 Sep; 66(9):826-9.
Score: 0.112
-
Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3.
Score: 0.108
-
Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010 Sep; 101(9):2005-10.
Score: 0.093
-
del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2009 Jul; 192(1):18-23.
Score: 0.086
-
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11.
Score: 0.076
-
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer. 2006 Apr 15; 106(8):1730-8.
Score: 0.069
-
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012 Oct; 25(10):1405-12.
Score: 0.026
-
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94.
Score: 0.020
-
inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol. 2005 Nov; 124(5):807-14.
Score: 0.017